Home > Haematology > ASH 2021 > Multiple Myeloma > iStopMM: Smouldering MM highly prevalent in general population

iStopMM: Smouldering MM highly prevalent in general population

Presented By
Dr Sigrún Thorsteinsdóttir, University of Iceland, Iceland
Conference
ASH 2021
Trial
iStopMM
A large, population-based study showed that smouldering multiple myeloma (MM) is highly prevalent in individuals 40 years or older. Approximately 1 out of 3 patients with smouldering MM may progress towards MM. These results display a need to improve treatment policies and risk stratification in patients with smouldering MM [1]. Smouldering MM is an asymptomatic, preliminary condition of MM. Screening for smouldering MM is currently not recommended. Therefore, few patients with MM are diagnosed at the smouldering stage of the disease. Yet, evidence indicates that treatment initiation at the smouldering stage of MM may be beneficial for health outcomes [2,3]. Dr Sigrún Thorsteinsdóttir (University of Iceland, Iceland) and colleagues aimed to map the epidemiological and clinical characteristics of smouldering MM. The large, population-based iStopMM study (NCT03327...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on